Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...

During the third quarter, Novavax entered into a material transfer agreement with a leading pharmaceutical company to ...

In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...

Novavax, a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, is proud to announce an exciting new partnership with the Los Angeles Rams aimed at "Protecting the Rams House" ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

The FDA lifted a clinical hold that had been placed on Novavax's investigational new drug application after the company addressed concerns related to a serious adverse event reported in a phase 2 ...

Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.

The vaccine maker posted a narrower third-quarter loss than expected at 76 cents a share. Revenue was $85 million, compared ...

Novavax's (NVAX) stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales for ...

"We were hopeful to get a larger market share this year," Novavax CEO John Jacobs said in an interview, adding the company ...